Salmón-Mulanovich G, Utz G, Lescano AG, Bentzel DE, Blazes DL

Language: English
References: 14
Page: 34-38
PDF size: 153.54 Kb.

ABSTRACT

Objective. To prevent transmission among the staff and potentially among the non-human primate (NHP) colony at the U.S. Naval Medical Research Center Detachment in Peru, where an active case of mumps was discovered in a senior laboratory technician in Sep 03, 2007. Material and Methods. Subjects at the research facility were interviewed and potentially susceptible contacts were tested for mumps IgG. Results. In total, 81 out of 106 staff members (76%) had close contact with the case. Only 6/81 (7%) had MMR, 33 (41%) reported having had mumps, and 8 of 45 (18%) of the potentially susceptible individuals did not have immunity (IgG › 20.0). All the susceptible, exposed individuals received MMR vaccine. There were no secondary cases and access to the NHP colony was restricted. Discussion. Immediate and thorough investigation and occupational health response were imperative in preventing secondary cases of mumps among humans and NHP.

REFERENCES

1. Saika S, Kidokoro M, Ohkawa T, Aoki A, Suzuki, K. Pathogenicity of mumps virus in the marmoset. J Med Virol 2002; 66(1): 115-122.

2. Johnson CD, Goodpasture EW. Experimental immunity to the virus of mumps in monkeys. Am J Epidemiol 1936; 23(2):329-339.

3. Findlay GM, Clarke LP. Experimental production of mumps in monkeys. Brit J Exp Pathol 1934; 15:309-313.

4. Enders JF, Kane LW, Cohen S, Levens J. Immunity in mumps: I. Experiments with monkeys (Macacus mulatta). The development of complement-fixing antibody following infection and experiments on immunization by means of inactivated virus and convalescent human serum. J Exp Med 1945; 81(1): 93-117.

5. Flanagan TD, Andrada JA, Barron AL, Witebsky E. Response to experimental infection with mumps virus in rhesus monkeys. Infect Immun 1971; 3(5):642-647.

6. Center for Disease Control and Prevention. Mumps outbreak at a summer camp--New York, 2005. MMWR Morb Mortal Wkly Rep 2006; 55(7): 175-177.

7. Sartorius B, Penttinen P, Nilsson J, Johansen K, Jonsson K, Arneborn M, et al. An outbreak of mumps in Sweden, February-April 2004. Euro Surveill 2005; 10(9): 191-193.

8. Caplan CE. Mumps in the era of vaccines. CMAJ 1999; 160(6):865-866.

9. Wilson TR, Fishbein D B, Ellis P A, Edlavitch S A. The impact of a school entry law on adolescent immunization rates. J Adolesc Health 2005; 37(6):511-516.

10. Clements C, Ratzan S. Misled and confused? Telling the public about MMR vaccine safety. Measles, mumps, and rubella. J Med Ethics 2003; 29(1): 22-26.

11. Center for Disease Control and Prevention. Mumps epidemic--Iowa, 2006. MMWR Morb Mortal Wkly Rep 2006; 55(13): 366-368.

12. Anderson RM, Crombie JA, Grenfell BT. The epidemiology of mumps in the UK: a preliminary study of virus transmission, herd immunity and the potential impact of immunization. Epidemiol Infect 1987; 99(1): 65-84.

13. Cohen CWJ, Savage EJ, Glynn JR, Choi Y, Andrews N, et al. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis 2007; 13(1). Available from http://www.cdc.gov/ncidod/EID/13/1/12.htm

14. Fernandez-de la Hoz-Zeitler K, Garcia-Colmenero C, Puchades- Belenguer M J, Verde-Lopez C, Carpintero-Redondo J L, Alcazar- Casanova F. Mumps epidemic in the health area of Toledo with immunization intervention. Estimation of vaccine effectiveness. Med Clin (Barc) 1997; 108(5): 175-179.